COMPASS-CABG: Rivaroxaban Not Linked with Preventing Outcomes After CABG

Low-dose rivaroxaban for the prevention of outcomes from coronary artery bypass graft (CABG) provided no additional benefit, according to new research.

The researchers, publishing in the Journal of the American College of Cardiology, conducted the COMPASS-CABG as a substudy of the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) trial looking specifically graft failure in patients who underwent CABG taking either rivaroxaban or aspirin. Participants in COMPASS-CABG (n=1,448) were enrolled four to 14 days after CABG surgery to either rivaroxaban plus aspirin, rivaroxaban alone, or aspirin alone. The primary study outcome was graft failure at a year post-surgery.

According to the results, the combination of aspirin plus rivaroxaban (P=0.45 for comparison), and rivaroxaban alone (P=0.75), were not associated with a reduction in graft failure rates compared to aspirin alone. Combination therapy was associated with a small trend toward reduction in major adverse cardiac events (P=0.34) when compared to aspirin alone, whereas rivaroxaban alone was not (P=0.98).

“The combination of rivaroxaban 2.5 mg twice daily plus aspirin or rivaroxaban 5 mg twice daily alone compared with aspirin alone did not reduce graft failure in patients with recent CABG surgery, but the combination of rivaroxaban 2.5 mg twice daily plus aspirin was associated with similar reductions in MACE, as observed in the larger COMPASS trial,” the researchers wrote in their conclusion.

Source: Journal of the American College of Cardiology